FEBS Letters

Molecular mechanism of stop codon recognition by eRF1: a wobble hypothesis for peptide anticodons
pp. 105-109(5)
Authors: Muramatsu^a T.; Heckmann^b K.; Kitanaka^a C.; Kuchino^a Y.

Hypoxia death stimulus induces translocation of p53 protein to mitochondria - Detection by immunofluorescence on whole cells
pp. 110-115(6)
Authors: Sansome C.; Zaika A.; Marchenko N.D.; Moll U.M.

The C-terminus of human glutaminase L mediates association with PDZ domain-containing proteins¹
pp. 116-122(7)
Authors: Olalla² L.; Aledo² J.C.; Bannenberg³ G.; Marquez J.

Hydroxyl radical-induced apoptosis in human tumor cells is associated with telomere shortening but not telomerase inhibition and caspase activation
pp. 123-132(10)
Authors: Ren^a J.-G.; Xia^a H.-L.; Just^b T.; Dai^a Y.-R.

Expression of telomerase inhibits hydroxyl radical-induced apoptosis in normal telomerase negative human lung fibroblasts
pp. 133-138(6)
Authors: Ren^a J.-G.; Xia^a H.-L.; Tian^a Y.-M.; Just^b T.; Cai^a G.-P.; Dai^a Y.-R.

Surprisingly high stability of barley lipid transfer protein, LTP1, towards denaturant, heat and proteases
pp. 145-148(4)
Authors: Lindorff-Larsen K.; Winther J.R.

Inhibitory serpins from rye grain with glutamine as P₁ and P₂ residues in the reactive center
pp. 149-153(5)
Author: Hejgaard J.

Antioxidant treatment induces transcription and expression of transforming growth factor in cultured renal proximal tubular cells
pp. 154-159(6)
Authors: Wolf^a G.; Hannken^a T.; Schroeder^a R.; Zahner^a G.; Ziyadeh^b F.N.; Stahl^a R.A.K.

Metabotropic receptors: ten years of research
pp. 159-159(1)
Author: Bockaert J.

Personality disorders are disorders of the personality?
pp. 159-160(2)
Author: Loacute pez-Ibor J.J.

Occurrence of ceramides and neutral glycolipids with unusual long-chain base composition in purified rat liver mitochondria
pp. 160-164(5)
Authors: Ardail^a D.; Popa^b1 I.; Alcantara^a K.; Pons^c A.; Zanetta^c J.P.; Louisot^a P.; Thomas^b L.; Portoukalian^b J.

The dopamine and glutamate hypotheses of schizophrenia -- therapeutic implications of an integrated view
pp. 160-160(1)
Author: Carlsson A.

Peripheral markers in obsessive-compulsive disorder: effect of treatments
pp. 161-161(1)
Authors: Marazziti D.; Pfanner C.; Rossi A.; Gemignani A.; Milanfranchi A.; Ravagli S.; Lensi P.; Presta S.; Cassano G.B.

The relevance of behavioral probes in obsessive-compulsive disorder
pp. 161-162(2)
Authors: Dolberg O.T.; Sasson Y.; Cohen R.; Zohar J.

Treating obsessive-compulsive disorder with serotonin reuptake inhibitors
pp. 162-163(2)
Author: Koran L.M.

The use of antiandrogen therapy in refractory obsessive-compulsive male patients
pp. 163-163(1)
Authors: Casas M.; Barcia D.; Vallejo J.; Turoacute n V.; Salorio P.; Ruiz E.; Duro P.; Tejero A.

Treatment of severe OCD
pp. 163-164(2)
Authors: Goodman W.K.; Byerly M.; Murphy T.

Imaging of neuroleptic occupancy in schizophrenia
pp. 164-164(1)
Authors: Kerwin R.; Pilowsky L.; Busatto G.; Costa D.; Ell P.

Movement disorders in schizophrenia: current considerations
pp. 164-165(2)
Author: Casey D.E.

Relationship between DNA methylation, histone H4 acetylation and gene expression in the mouse imprinted Igf2-H19 domain
pp. 165-169(5)
Authors: Grandjean^a V.; O'Neill^b L.; Sado^a T.; Turner^b B.; Ferguson-Smith^a A.

Health economic considerations in the treatment of schizophrenia
pp. 165-165(1)
Author: Souetre E.

Update on new atypical antipsychotics
pp. 165-165(1)
Author: Tollefson G.D.

Reintegration strategies in schizophrenia: maximizing outcomes
pp. 165-166(2)
Author: Littrell K.H.

Alpha-2 adrenergic dysfunction in depression: standardization and validation of the clonidine REM suppression test (CREST)
pp. 166-166(1)
Author: Schittecatte M.

Affective disorder treatments and second messengers in the brain
pp. 167-167(1)
Authors: Moslashrk A.; Jensen J.B.; Petersen B.; Thrane J.; Geisler A.

The comparative effects of SSRIs and TCAs on sleep architecture
pp. 167-168(2)
Author: Nutt D.J.

The stress-induced anhedonia model of depression predicts antidepressant-like properties of the COMT inhibitor tolcapone
pp. 168-168(1)
Authors: Moreau J.-L.; Jenck F.; Martin J.R.; Mutel V.; Da Prada M.

Long-term SSRI treatment increases Ca²⁺/calmodulin phosphorylation of presynaptic proteins: a new site in the mechanism of action of antidepressants
pp. 168-169(2)
Authors: Popoli M.; Vocaturo C.; Buffa L.; Pereza J.; Racagni G.

Molecular pharmacology of NMDA receptors
pp. 169-169(1)
Author: Williams K.

Therapeutic potential of drugs acting on excitatory amino acid receptors
pp. 169-170(2)
Authors: Scatton B.; Avenet P.; Benavides J.; Besnard F.; Carter C.; Duverger D.; Graham D.; Leacute onardon J.; Santa-Maria R.; Langer S.Z.

Identification of gcpE as a novel gene of the 2-C-methyl-D-erythritol 4-phosphate pathway for isoprenoid biosynthesis in Escherichia coli
pp. 170-173(4)
Authors: Campos^a N.; Rodrguez-Concepcion^a M.; Seemann^b M.; Rohmer^b M.; Boronat^a A.

Glutamate antagonists in animal models of cerebral ischaemia
pp. 170-170(1)
Author: McCulloch J.

The pharmacology of CERETAT^TM (CNS1102) and early clinical results
pp. 171-171(1)
Author: Gamzu E.

Clinical treatment of ischaemic stroke: present and future
pp. 171-172(2)
Authors: Fieschi C.; Cavalletti C.; Montinaro E.

Depression and the risk of mortality
pp. 172-172(1)
Author: Glassman A.H.

Treatment response to serotonin reuptake inhibitors in minor depressions
pp. 172-173(2)
Author: Rosenbaum J.F.

SSRIs in the treatment of melancholic patients
pp. 173-173(1)
Authors: Roose S.P.; Glassman A.H.; Attia E.

The optimal therapeutical area for SSRIs: panic disorder
pp. 173-174(2)
Author: Wade A.G.

IGF-1 receptor as an alternative receptor for metabolic signaling in insulin receptor-deficient muscle cells
pp. 174-178(5)
Authors: Baudry^a A.; Lamothe^a B.; Bucchini^a D.; Jami^a J.; Montarras^b D.; Pinset^b C.; Joshi^a R.L.

Obsessive compulsive disorder (OCD) and social phobia
pp. 174-174(1)
Author: Ballenger J.C.

Differences between the SSRI
pp. 174-174(1)
Author: Broslashsen K.

WHO international study of somatoform disorders -- a review of methods and results
pp. 175-175(1)
Author: Janca A.

Somatoform disorders and personality in the general population and in psychiatric outpatients
pp. 175-175(1)
Author: Cloninger C.R.

The present nosography of somatoform disorders: results of the Italian epidemiological study of somatoform disorders
pp. 175-176(2)
Authors: Tacchini G.; Musazzi A.; Recchia M.; Altamura A.C.; Carta M.G.

The co-occurrence of panic and somatization disorder: analysis from a genetic-epidemiological vantage point
pp. 176-176(1)
Authors: Battaglia M.; Politi E.; Bertella S.; Bellodi L.

Psychopharmacological treatments of somatoform disorders
pp. 176-177(2)
Author: Altamura A.C.

Focus on biological basis of somatoform disorders
pp. 177-177(1)
Authors: Del Zompo M.; Ruiu S.; Severino G.; Cherchi A.; Bocchetta A.; Usaia P.

New perspectives on physiopathology and therapy of somatoform diseases
pp. 177-177(1)
Authors: Fratta W.; Mancinelli R.; Diana M.; Azzena G.B.; Forgione A.

Impulse control and serotonergic drugs: commonalities and differences in animal models
pp. 177-178(2)
Authors: De Vry J.; Schreiber R.; de Beun R.

Clinical, nonhuman primate and rodent studies on impulse control
pp. 178-178(1)
Authors: Linnoila M.; Higley J.D.; Hall F.S.; Weight F.; Nielsen D.; Goldman D.; Virkkunen M.

Therapeutic attempts in impulse control disorders
pp. 178-179(2)
Authors: Loacute pez-Ibor J.J.; Ruiacute z J.S..

Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells
pp. 179-184(6)
Authors: Gao^a B.; Shen^a X.; Kunos^a G.; Meng^b Q.; Goldberg^b I.D.; Rosen^b E.M.; Fan^b2 S.

Platelet markers in aggression
pp. 179-180(2)
Authors: Oerlinghausen B.M..; Uebelhack R.

Psychiatric effects of the anabolic steroids: aggression and impulse dyscontrol
pp. 180-180(1)
Authors: Katz D.L.; Pope H.G.

Multiple ATP receptors in the nervous system: new and widely-distributed drug targets
pp. 180-180(1)
Author: Barnard E.A.

Regulation of gene expression in adult brain
pp. 180-181(2)
Authors: Vanderhaeghen J.J.; Schiffmann S.N.; Mailleux P.; Zhang F.; Van Breacute e L.

Regulatory mechanisms of neurotrophic factor gene expression in the central nervous system
pp. 181-181(1)
Authors: Riva M.A.; Molteni R.; Lovati E.; Fumagalli F.; Racagni G.

Functional and pharmacological distinctions between subtypes of dopamine D-2 receptors
pp. 181-182(2)
Authors: Spano P.F.; Memo M.; Missale C.; Pizzi M.; Sigala S.; Valerio A.

Provocation of panic as a tool for investigating the disorder
pp. 183-183(1)
Author: Bourin M.

Panic disorder and the serotonin system
pp. 183-184(2)
Authors: Westenberg H.G.M.; den Boer J.A.

SSRIs in panic disorder
pp. 184-184(1)
Author: Lecrubier Y.

The relationship between panic and agoraphobia
pp. 184-185(2)
Author: Klein D.F.

Site-directed mutagenesis of K396R of the 65 kDa glutamic acid decarboxylase active site obliterates enzyme activity but not antibody binding
pp. 185-189(5)
Authors: Hampe^a C.S.; Hammerle^a L.P.; Falorni^b A.; Robertson^c J.; Lernmark^a A.

Carbon dioxide hypersensitivity and panic spectrum disorders
pp. 185-185(1)
Authors: Perna G.; Bellodi L.

Has the response of positive symptoms to antipsychotics changed?
pp. 185-186(2)
Author: Kane J.M.

Are primary negative symptoms treatable?
pp. 186-187(2)
Authors: Barnes T.R.E.; Phillips M.A.

Quality of life as an outcome variable in the treatment of schizophrenic patients
pp. 187-187(1)
Authors: Meise U.; Kemmler G.; Holzner B.

Movement disorders -- do [ldquo ]atypical[rdquo ] antipsychotics make a difference?
pp. 187-188(2)
Author: Gerlach J.

Advantages of atypical antipsychotics in the maintenance treatment of schizophrenia
pp. 188-188(1)
Author: Kissling W.

Pharmacodynamic and pharmacokinetic profile of an [ldquo ]ideal[rdquo ] neuroleptic: is there any?
pp. 188-188(1)
Author: Altamura A.C.

Broadening treatment perspectives of schizophrenia: a clinical update on seroquel
pp. 189-189(1)
Author: Fleischhacker W.W.

When do antidepressants work?
pp. 189-189(1)
Author: Derivan A.T.

Early improvement predicts response
pp. 189-190(2)
Author: Bech P.

Identification and characterization of functional domains in a mixed lineage kinase LZK
pp. 190-195(6)
Authors: Ikeda A.; Masaki M.; Kozutsumi Y.; Oka S.; Kawasaki T.

Protein phosphorylation system as a biochemical marker to study onset of antidepressant action
pp. 190-190(1)
Authors: Perez J.; Mori S.; Caivano M.; Garbini S.; Dorigo A.; Popoli M.; Brunello N.; Smeraldi E.; Racagni G.

Can two week studies be used to establish efficacy?
pp. 190-191(2)
Author: Montgomery S.A.

Enhanced antidepressant responses with antagonists of somatodendritic 5-HT_1A receptors. Basic and clinical studies
pp. 191-191(1)
Authors: Artigas F.; Romero L.; Bel N.; Peacute rez V.; Alvarez E.

Therapeutic strategies for rapid onset and improved efficacy: present and future
pp. 191-192(2)
Author: de Montigny C.

Animal models in alcohol research
pp. 192-192(1)
Authors: Colombo G.; Agabio R.; Balaklievskaia N.; Lobina C.; Reali R.; Fadda F.; Gessa G.L.

Is there a role for neurosteroids in alcoholism?
pp. 192-193(2)
Authors: Romeo E.; Pompili E.; di Michele F.; Furnari C.; Fucci P.; Pasini A.

Carbohydrate deficient transferrin (CDT) in comparison to other biological markers in alcoholism
pp. 193-194(2)
Authors: Ackenheil M.; Sanktjohannser A.; Soyka M.; Jenner A.; Karlsson M.

Pharmacotherapeutic approaches in relapse prevention
pp. 194-194(1)
Author: Chick J.D.

Basic and clinical research leading to the use of naltrexone in the treatment of alcoholism
pp. 194-195(2)
Authors: O'Brien C.P.; Volpicelli J.R.

Experience with naltrexone and psychotherapy in treating alcoholism in Europe
pp. 195-195(1)
Author: Soyka M.

Dopamine D1 receptor activation decreases GABA release through adenosine A1 receptor after chronic cocaine treatment
pp. 196-196(1)
Authors: Williams J.T.; Bonci A.

Somatodendritic dopamine stimulates glutamate and GABA release via D₁ receptors
pp. 196-196(1)
Authors: Kalivas P.W.; X.-Y. L.

Functional role of somatodendritic dopamine release in basal ganglia circuitry
pp. 196-196(1)
Authors: Abercrombie E.D.; Timmerman W.; DeBoer P.

Involvement of the nigral D₁ receptor in neuroleptic-induced oral dyskinesias in rats: clinical implications
pp. 196-197(2)
Author: Tamminga C.A.

Subthreshold syndromes of depression
pp. 197-197(1)
Authors: Preisig M.; Angst J.; Merikangas K.R.

Do antidepressants work in mild depression?
pp. 197-198(2)
Author: Montgomery S.A.

Acute and long-term pharmacotherapeutic strategies in pure dysthymia: efficacy of sertraline and imipramine
pp. 198-198(1)
Author: Kocsis J.

Cross-over studies of chronic resistant depression
pp. 198-199(2)
Authors: Keller M.; Zucker M.E.

Pharmacotherapy of depression subtypes
pp. 199-199(1)
Author: Kasper S.

Managing the first episode of schizophrenia: the role of new therapies
pp. 200-200(1)
Author: McCreadie R.G.

Cognitive dysfunction in schizophrenia: comparison of treatment with a novel atypical antipsychotic agent versus conventional neuroleptic drugs
pp. 200-201(2)
Author: Gallhofer B.

Identification of two proteins, S14 and UIP1, that interact with UCH37
pp. 201-205(5)
Authors: Li T.; Duan W.; Yang H.; Lee M.-K.; Bte Mustafa F.; Lee B.-H.; Teo T.-S.

Treatment resistant schizophrenia: new insights into neurobiology and treatment
pp. 201-201(1)
Authors: Weinberger D.R.; Lipska B.K.

Treatment-resistant schizophrenia: clinical experience with new antipsychotics
pp. 202-202(1)
Authors: Dufour H.; Bondolfi G.; Baumann P.; Seywert F.

Proper psychosocial rehabilitation for the stabilised schizophrenic patients: the role of new therapies
pp. 202-203(2)
Author: Peuskens J.

The impact of managed care systems on relapse prevention and quality of life for patients with schizophrenia
pp. 203-203(1)
Author: Glazer W.M.

Underlying neurotransmitter changes in Alzheimer's disease
pp. 203-204(2)
Authors: Francis P.T.; Alder J.T.; C. P.L.-H.C.; Chessell I.P.; Clarke N.A.; Dijk S.N.; Procter A.W.; Webster M.-T.; Bowen D.M.

Alzheimer's disease: neurochemistry of Alzheimer's disease and its clinical implications
pp. 204-204(1)
Author: Amaducci L.

Treatment strategies in Alzheimer's disease
pp. 204-205(2)
Author: Levy R.

Xanomeline: the first study of the safety and efficacy of an M1 agonist in mild and moderate Alzheimer's disease
pp. 205-205(1)
Authors: Bodick N.C.; Offen W.

Disease altering therapeutic strategies based on the molecular dissection of the amyloid lesions in Alzheimer's disease
pp. 205-206(2)
Authors: Beyreuther K.; Masters C.L.

Aspirin promotes TFF2 gene activation in human gastric cancer cell lines
pp. 206-210(5)
Authors: Azarschab P.; Al-Azzeh E.-d.; Kornberger W.; Gott P.

Defective protein kinase C [alpha ] and [beta ]-amyloid precursor protein secretion in fibroblasts from sporadic Alzheimer's disease patients
pp. 206-206(1)
Authors: Govoni S.; Bergamaschi S.; Trabucchi M.; Battaini F.; Binetti G.; Bianchetti A.; Racchi M.

Pharmacological treatment of anxiety disorders: an overview
pp. 206-207(2)
Authors: Leacute pine J.P.; Pelissolo A.

MAOIs in social phobia
pp. 207-207(1)
Authors: Katschnig H.; Berger P.

Benzodiazepines in panic disorders: focus on clonazepam
pp. 207-208(2)
Author: Rosenbaum J.F.

Are there more effective drug treatments for obsessive compulsive disorder?
pp. 208-208(1)
Authors: Fineberg N.A.; Roberts A.; Montgomery S.A.

5HT2C receptor agonists and antagonists in animal models of anxiety
pp. 209-209(1)
Authors: Martin J.R.; Bouml s M.; Jenck F.; Kouml hler C.; Moreau J.-L.; Sleight A.J.; Stadler H.; Wichmann J.

The role of serotonin in dysthymia and other affective spectrum diseases
pp. 209-210(2)
Author: Kasper S.

Role of serotonin in psychosis
pp. 210-210(1)
Authors: Farde L.; Nyberg S.; Halldin C.

OCD: the promise and limitation of serotonin selective agents
pp. 210-210(1)
Author: Ravizza L.

Premenstrual mood disorders: clinical experience with serotonergic-based therapies
pp. 210-211(2)
Author: Steiner M.

Pathogen-induced expression of plant ATP:citrate lyase¹
pp. 211-212(2)
Authors: Suh^a M.C.; Yi^b S.Y.; Lee^b S.; Sim^a W.-S.; Pai^b H.S.; Choi^b D.

The role of serotonin in emerging therapeutic opportunities: the beginning not the end
pp. 212-213(2)
Author: Tollefson G.D.

Novel neuroleptics acting on presynaptic dopaminergic receptors
pp. 213-213(1)
Authors: Scatton B.; Perrault G.; Gonon F.; Depoortere R.; Sanger D.; Schoemaker H.

Pharmacology of anhedonia
pp. 214-214(1)
Author: Willner P.

Acute and long-term treatment of schizophrenia: different strategies for positive and negative symptoms?
pp. 216-216(1)
Author: Rein W.

Assessment of negative symptoms in the long-term treatment of psychosis
pp. 216-217(2)
Author: Kane J.M.

Endogenous cannabinoid ligands -- chemical and biological studies
pp. 217-217(1)
Authors: Mechoulam R.; Shabat S.B.; Hanuscaron L.; Fride E.; Barg Y.; Vogel Z.; Bayewitch M.

GABAergic drugs and addictive behavior
pp. 217-218(2)
Authors: Tempesta E.; Janiri L.; Mannelli P.

Opioid receptor blockade
pp. 218-218(1)
Author: Kosten T.R.

Is dopamine involved in opiate addiction?
pp. 218-219(2)
Authors: van Ree J.M.; Gerrits M.A.F.M.

Opiate agonists and antagonists in the treatment of heroin addiction: differential outcomes according to methadone and naltrexone treatment practice
pp. 219-219(1)
Authors: Mannaioni P.F.; Botti P.; Caramelli L.; Gambassi F.; Occupati B.; Peruzzi S.; Pistelli A.; Smorlesi C.; Zorn A.M.; Masini E.

The impact of depression on survival following myocardial infarction
pp. 219-220(2)
Authors: Lespeacute rance F.; Smith N.F.; Talajic M.

Vital exhaustion, cardiac events, and the relationship to depression
pp. 220-221(2)
Author: Kop W.J.

Anger, hostility and progression of arteriosclerotic disease
pp. 221-221(1)
Authors: Kaplan G.A.; Salonen J.T.; Julkunen J.; Kauhanen J.; Salonen R.

Mechanisms linking death and depression
pp. 221-222(2)
Authors: Glassman A.H.; Bigger J.T.; Roose S.P.

Can antidepressants be used safely in patients with serious heart disease?
pp. 222-222(1)
Authors: Roose S.P.; Glassman A.H.; Woodring S.

Plasticity of astrocytes in aging
pp. 222-223(2)
Authors: Vernadakis A.; Kentroti S.; Kazazoglou T.; Lambropoulos E.F.; Geladopoulos T.; Stefanis C.

Growth factors as products and regulators of astrocytes: CNTF, FGF, TGF-[beta ]1-3, and GDNF
pp. 223-223(1)
Authors: Unsicker K.; Meyer V.; Flanders K.C.; Wirth S.B.; Rufer M.; Krieglstein K.; Suter-Crazzolara C.

Oxysterol (7[beta ]-hydroxycholesteryl-3-oleate) promotes serotonergic reinnervation in the lesioned rat spinal cord by reducing glial reaction
pp. 223-223(1)
Authors: Privat A.; Gimenez y Ribotta M.; Mersel M.

Neuron-glia interactions in glutamate and GABA homeostasis: implications for epilepsy and neurodegenerative diseases
pp. 224-224(1)
Author: Schousboe A.

Enhanced extracellular glutamate and delayed neurotoxicity in cortical neuroglial cocultures exposed to the glutamate uptake inhibitor PDC
pp. 224-224(1)
Authors: Volterra A.; Bezzi P.; Rizzini B.L.; Trotti D.; Rossi D.; Racagni G.

Prevalence, lifecourse and disability in social phobia
pp. 224-225(2)
Author: Judd L.L.

WPA educational programme on social phobia
pp. 225-225(1)
Author: e Silva J.A.C.

Reversible inhibitors of monamine oxidase A (RIMA) in the treatment of social phobia
pp. 226-226(1)
Author: Siegel J.L.

Interaction of drugs and psychotherapy in social phobia
pp. 227-227(1)
Authors: Katschnig H.; Sachs G.

Subclinical and atypical forms of bipolarity
pp. 227-227(1)
Author: Cassano G.B.

Distinction of recurrent brief depression from other fluctuating brief depressions. Consequences for therapy evaluation
pp. 227-228(2)
Authors: Benkert O.; Fickinger M.P.; Philipp M.; Heun R.

Is rapid cycling a valid subtype of bipolar disorder?
pp. 228-228(1)
Authors: Maj M.; Magliano L.; Pirozzi R.; Marasco C.; Guarneri M.

New treatments for bipolar disorder
pp. 228-229(2)
Author: Tohen M.

Evidence of the efficacy of maintenance-electroconvulsive therapy (M-ECT) in rapid cycling bipolar disorders
pp. 229-229(1)
Authors: Vanelle J.M.; de Carvalho W.; Olieacute J.P.; Locirc o H.

Functional organization of the ventral striatum: focus on limbic-striatal loops
pp. 229-229(1)
Author: Everitt B.J.

Physiological function of the ventral striatum
pp. 229-230(2)
Authors: Le Moal M.; Piazza P.V.; Maccari S.; Casolini P.; Rougeacute -Pont F.; Simon H.

Abnormal mesolimbic dopamine function following neonatal hippocampal damage: implications for schizophrenia
pp. 230-230(1)
Authors: Lipska B.K.; Lillrank S.M.; Wood G.K.; Weinberger D.R.

Dopaminergic hypofunction in the nucleus accumbens as a substrate for depression
pp. 230-231(2)
Author: Willner P.

Prefronto-cortical versus ventral striatal selectivity in the action of motivationally active drugs and stimuli
pp. 231-232(2)
Author: Di Chiara G.

Free radical scavengers in neuroprotection
pp. 232-232(1)
Authors: Riederer P.; Gsell W.; Frouml lich L.; Gouml tz M.

Physiopathological role of glutamate receptors in mesencephalic neurons in vitro
pp. 232-233(2)
Authors: Ambrosini A.; Bresciani L.; Orlandi V.; Fracchia S.; Racagni G.; Brunello N.

Evoked potentials monitoring in Parkinson's disease therapy
pp. 233-234(2)
Authors: Stanzione P.; Pierantozzi M.; Semprini R.; Traversa R.; Bernardi G.

Electrophysiological monitoring of dopaminergic therapy using short-latency median nerve somatosensory evoked potentials (SEPS) in Parkinson's disease
pp. 234-234(1)
Author: Mauguiegrave re F.

The effect of treatment on motor cortical activity in Parkinson's disease
pp. 234-235(2)
Author: Rothwell J.C.

Age-dependent behaviors and developmental psychopharmacology in the context of behavioral teratology
pp. 235-235(1)
Author: Spear L.P.

Psychoactive drugs and early social interactions in rodents
pp. 235-236(2)
Authors: Laviola G.; Terranova M.L.

The role of behavior in the assessment of developmental neurotoxicity in humans and animals
pp. 236-236(1)
Author: Elsner J.

Neurobehavioral changes produced by developmental exposure to environmental pollutants
pp. 236-237(2)
Authors: De Salvia M.A.; Carratugrave M.R.; Cagiano R.; Cortese I.; Renna G.; Siro-Brigiani G.; Cuomo V.

Ontogeny of firing patterns of dopamine neurons in rat midbrain slices. Role of NMDA receptor activation
pp. 237-238(2)
Authors: Mereu G.; Casula A.; Lilliu V.; Vicini S.; Francesconi W.; Gessa G.L.

Animal models of developmental neurotoxicity and their relevance to human exposures: the example of lead
pp. 238-238(1)
Authors: Winneke G.; Lilienthal H.; Bonatz A.

Anatomical abnormalities in the temporal lobe in schizophrenia
pp. 238-239(2)
Authors: Shenton M.E.; McCarley R.W.; Kikinis R.; Hokama H.H.; Nestor P.G.; O'Donnell B.F.; Dickey C.C.; Wible C.G.; Jolesz F.A.

Magnetic resonance imaging of the frontal lobe in schizophrenia
pp. 239-239(1)
Authors: Pol H.E.H.; Baareacute W.F.C.; Gispen-de Wied C.C.; Mali W.P.T.M.; Kahn R.S.

Receptor binding studies in schizophrenia
pp. 239-240(2)
Author: Sedvall G.

Neuroanatomical abnormalities and symptomatology of schizophrenia
pp. 240-240(1)
Authors: Vita A.; Dieci M.; Giobbio G.M.; Caputo A.; Ghiringhelli L.; Tenconi F.; Comazzi M.; Invernizzi G.

Basal ganglia shrinkage in schizophrenia: magnetic resonance and neuropsychological study
pp. 240-241(2)
Authors: Rossi A.; Stratta P.; Mancini F.; Mattei P.; Daneluzzo E.; Casacchia M.

Functional neuroimaging to evaluate atypical antipsychotic compounds: an FDG PET study of SDZ MAR 327
pp. 241-242(2)
Authors: Potkin S.G.; Wu J.; Fallon F.; Bera R.; Carreon D.; Telford J.; Plon L.; Keator D.; Anand R.; Hartman R.

Life events and the aetiology of depression
pp. 242-242(1)
Author: Brown G.W.

Mechanisms of chronic mild stress-induced anhedonia
pp. 242-242(1)
Author: Papp M.

Implication of central and peripheral glutamate receptors in experimental stress ulcers
pp. 243-244(2)
Authors: Baraldi M.; Truzzi C.; Veneri C.; Chiessi C.; Cannazza G.; Zanoli P.

Tumorigenesis and immune function in a transgenic mouse model of the endocrine changes seen in depression characterized by defective glucocorticoid feedback inhibition and HPA axis hyperactivity
pp. 244-244(1)
Authors: Blom J.M.C.; Barden N.; Racagni G.

Influence of stress and glucocorticoids on psychostimulant abuse
pp. 244-245(2)
Authors: Piazza P.V.; Deroche V.; Rouge-Pont F.; Haney M.; Maccari S.; Le Moal M.

ECT in Parkinson's disease, with and without depression
pp. 245-245(1)
Author: Trimble M.R.

Psychopathology and prevalence of depression in Parkinson's disease
pp. 245-245(1)
Author: Ring H.A.

Interactions between dopaminergic, serotoninergic and nitric oxide-containing systems in the CNS. Their possible involvement in Parkinson's disease and depression
pp. 245-246(2)
Author: Steinbusch H.W.M.

Treatment of depression in Parkinson's disease: a meta-analysis
pp. 246-246(1)
Authors: Verhey F.R.J.; Havermans A.G.M.; Klaassen T.; van Praag H.M.

Parkinson's disease and depression: one disease?
pp. 246-246(1)
Authors: Martignoni E.; Verri A.P.; Nappi G.

The biological basis and pharmacological treatment of anxiety: do the elderly differ?
pp. 247-247(1)
Author: Leonard B.E.

Clinical aspects of anxiety states in the elderly
pp. 247-248(2)
Authors: Casacchia M.; Roncone R.

The clinical decision in long-term treatment of anxiety disorders with benzodiazepines
pp. 248-248(1)
Authors: Pancheri P.; Biondi M.

The treatment of anxiety disorders in the elderly
pp. 248-249(2)
Authors: Sheehan D.V.; Ray B.A.; Sheehan K.H.

Chronicity and continuity in depressive state
pp. 249-249(1)
Authors: Cassano G.B.; Cecconi D.

Pharmacological and clinical experience in nefazodone treatment of depression
pp. 249-250(2)
Author: Preakorn S.H.

Modern approach in the treatment of anxiety associated with depression
pp. 250-250(1)
Author: Keller M.B.

The effects of nefazodone on sleep profiles in depression
pp. 250-250(1)
Author: Armitage R.

Sexual dysfunction and other tolerability in the management of depression
pp. 250-251(2)
Author: Baldwin D.

Sleep and neuroendocrine profiles in depression and mania
pp. 251-251(1)
Authors: Linkowski P.; Mendlewicz J.

Preclinical/clinical aspects of interactions between serotonin and norepinephrine
pp. 251-251(1)
Author: Blier P.

Pharmacotherapeutic profile of venlafaxine
pp. 251-252(2)
Author: Preskorn S.H.

Rapid onset of action: clinical relevance to antidepressant action
pp. 252-253(2)
Author: Montgomery S.A.

Efficacy and safety of venlafaxine in major depression
pp. 253-254(2)
Author: Lecrubier Y.

An overview of CNS drug discovery at Eli Lilly and Company
pp. 254-254(1)
Author: Paul S.M.

The discovery and pharmacology of xanomeline, a muscarinic M1 receptor agonist for Alzheimer's disease
pp. 254-254(1)
Authors: Shannon H.E.; Bymaster F.P.; Calligaro D.O.; DeLapp N.W.; Mitch C.H.; Ward J.S.; Olesen P.; Sheardown M.J.; Swedberg M.D.B.; Sauerberg P.

Xanomeline in mild and moderate Alzheimer's disease; the effects of a novel M1 agonist on behavior
pp. 254-255(2)
Authors: Bodick N.C.; Offen W.

Olanzapine: an exciting atypical antipsychotic -- the preclinical profile
pp. 255-256(2)
Authors: Moore N.A.; Bymaster F.P.; Calligaro D.O.; Fuller R.W.; Rasmussen K.; Stockton M.E.; D. T.W.; Tye N.C.

Olanzapine: an exciting atypical antipsychotic -- the clinical experience
pp. 256-256(1)
Authors: Tollefson G.D.; Beasley C.M.; Tran P.V.; Sanger T.

A randomized, naturalistic cost-effectiveness study in a managed health care setting
pp. 256-257(2)
Authors: Heiligenstein J.H.; Simon G.

Biological enrichment in the study of drug: placebo differences of patients with affective disorders
pp. 257-257(1)
Authors: James S.; Heiligenstein J.; Faries D.; Tollefson G.

Adaptive randomization in clinical trials: a placebo compromise
pp. 257-258(2)
Authors: Wood A.; Faries D.; Heiligenstein J.

A double-blind, placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder
pp. 258-258(1)
Author: Blashko C.A.

Premenstrual dysphoric disorder: is it simply PMS?
pp. 259-259(1)
Author: Endicott J.

The role of continuation treatment in chronic depression
pp. 259-260(2)
Authors: Keller M.; Zucker M.E.

Advances in the pharmacotherapy of obsessive-compulsive disorder
pp. 260-260(1)
Author: Bisserbe J.C.

The role of SSRIs in anxiety disorders
pp. 260-261(2)
Author: Nutt D.

Epidemiology and public health significance of depressive disorders
pp. 261-262(2)
Author: Judd L.L.

Neurobiology of antidepressant treatments
pp. 262-262(1)
Author: de Montigny C.

The new antidepressant Org 3770 (mirtazapine) modulates noradrenergic and serotonergic transmission by blocking [alpha ]₂-adrenergic autoreceptors
pp. 262-262(1)
Authors: de Boer T.; Nefkens F.; van Helvoirt A.

Clinical efficacy of mirtazapine: a review
pp. 262-263(2)
Author: Kasper S.

Safety of mirtazapine: a review
pp. 263-264(2)
Author: Montgomery S.A.

Lithium-potassium cotransport across the erythrocyte membrane in affective disorders
pp. 265-265(1)
Authors: Hiyama T.; Yoshimuta N.; Nakayama K.; Ushijima s.

Guanine nucleotide binding proteins (G proteins) in drug-free depressed patients
pp. 265-265(1)
Authors: Karege F.; Bovier P.; Schwald M.; Stepanian R.; Hilleret H.; Gaillard J.M.

Assessment of changes in regional cerebral blood flow in patients with seasonal affective disorder (SAD) using single photon emission tomography
pp. 265-266(2)
Authors: Rieder N.; Neumeister A.; Podreka I.; Kasper S.

The effects of CCK-4 on plasma arginine-vasopressin and oxytocin levels in women with and without premenstrual dysphoric disorder
pp. 266-266(1)
Authors: Le Melleacute do J.M.; Bradwejn J.; Koszycki D.; Bellavance F.; Steinberg S.; Halbreich U.; Legrand J.-M.; Bichet D.G.

Enhanced sensitivity to CCK-4 in women with severe premenstrual symptoms (PDD)
pp. 266-266(1)
Authors: Le Melleacute do J.M.; Bradwejn J.; Koszycki D.; Bellavance F.; Bichet D.G.; Halbreich U.; Steinberg S.; Legrand J.-M.

The prevalence of psychotropic drug use in the population presenting to general practitioner in the urban area of Padua
pp. 266-266(1)
Authors: Borgherini G.; Semenzin M.; Gardellin F.; Pavan L.; Giorgetti R.; Ferrara S.D.

Clinical predictors of response to antidepressants in geriatric depressions
pp. 266-267(2)
Authors: Koncevoy V.A.; Andrusenko M.P.; Sheshenin V.S.

Thyrotropin response to thyrotropin-releasing hormone in depression: thyroidological aspects
pp. 267-267(1)
Author: Bunevicius R.

ACTH, prolactin, cortisol after dexamethasone in mental illnesses with postmenopausal onsets
pp. 267-267(1)
Author: Molnaacute r G.

Clinical efficacy of left and right unilateral electroconvulsive seizures in affective disorders and schizophrenia
pp. 267-268(2)
Authors: Nikolaenko N.N.; Egorov A.Y.

Evolution of platelet and plasma serotonin levels following electroconvulsive therapy in patients with major depressive episode
pp. 268-268(1)
Authors: Quintin P.; Spreux-Varoquaux O.; Kollenbach K.; Gregoire A.; Advenier C.; Chevalier J.F.

Space perception changes as a result of cognitive dysfunction in affective disorders and schizophrenia
pp. 268-268(1)
Authors: Egoroy A.Y.; Nikolaenko N.N.; Freiman E.A.; Dobrovoslkaya N.V.

Eye fixations and recognition memory in depression
pp. 268-269(2)
Authors: Fleury E.; Buquet C.; Thomas P.; Goudemand M.; Hache J.C.; Charlier J.R.

Prevalence of psychiatric comorbidity in patients with diabetes mellitus type I with and without poor metabolic control
pp. 269-269(1)
Authors: Eiber R.; Balssa N.; Grimaldi A.; Lecrubier Y.; Bisserbe J.C.

Short-term availability of brain serotonin is crucial for antidepressant effect of light therapy
pp. 269-269(1)
Authors: Neumeister A.; Rieder N.; Hesselmann B.; Kasper S.

Light therapy is able to prevent the relapse after partial sleep deprivation
pp. 269-269(1)
Authors: Neumeister A.; Rieder N.; Gouml ssler R.; Lucht M.; Kapitany T.; Kasper S.

Cerebral blood flow pattern of treatment responsiveness in major depression
pp. 270-270(1)
Authors: Thomas P.; Vaiva G.; Maron M.; Baux P.; Notardonato L.; Rescle C.; Dutoit D.; Goudemand M.; Steinling M.

Cortical and subcortical brain changes in bipolar affective disorders: a magnetic resonance imaging study
pp. 270-270(1)
Authors: Puzdot ynacute ski S.; Berecedil sewicz M.; Koszewska I.; Poniatowska R.; Kryst-Widzacute gowska T.

Plasma prolactin level in major depression and antidepressant therapy
pp. 270-270(1)
Authors: Landowski J.; Sowinnacute ski P.; Wichowicz H.

The depression unknown to the general practitioner
pp. 270-271(2)
Authors: Zdanowicz N.; Reynaert C.; Janne P.; Boriani M.; Vause M.

Case report: mood disorder with maniac features in a patient treated with GM-C.S.F.
pp. 271-271(1)
Authors: Zdanowicz N.; Chatelain C.; Wulleman P.; Reynaert C.; Janne P.; Vause M.

Three months activity report of 104 Italian pychiatric centres
pp. 271-271(1)
Authors: Pancheri P.; Marconi P.L.

Study of anticipation in bipolar affective disorder
pp. 271-272(2)
Authors: Heiden A.M.; Miller-Reiter E.; Willinger U.; Meszaros K.; Scharfetter J.; Lenzinger E.; Resinger E.; Aschauer H.N.; Kasper S.

Suicidal behavior in depression: role of serotonin and noradrenaline
pp. 272-272(1)
Authors: Pitchot W.; Ansseau M.; Hansenne M.; Moreno A.G.

Depression and suicide on gotland, before and after the depression-training program for general practitioners
pp. 272-272(1)
Authors: Rihmer Z.; Pihlgren H.; Rutz W.

Endothelium released factors in depression
pp. 272-273(2)
Authors: D'Amato C.C.; Bianchi A.; Pitari G.M.; Candido P.; Rapisarda V.

Depression and direct central serotonin (B-HT)
pp. 273-273(1)
Authors: Becker U.; Laakmann G.; Baghai T.; Pfeiffer B.; Kauert G.

Treatment resistant depression -- a biochemical hypothesis
pp. 273-273(1)
Authors: Norman T.; Gupta R.K.; Burrows G.D.

Red blood cell L-tryptophan uptake in depression: a putative indicator of the antidepressant drug choice?
pp. 273-273(1)
Authors: Jeanningros R.; Serres F.; Azorin J.M.; Dassa D.; Noel F.

Are Wistar-Kyoto rats a genetic animal model of depression?: similarities with humans in the temporal response to imipramine
pp. 274-274(1)
Author: Lahmame A.

Additive effects of glyburide and antidepressants in the forced swimming test: further evidence for involvement of the potassium channels
pp. 274-274(1)
Authors: Guo W.Y.; Todd K.; Bourin M.; Hascoeuml t M.

Influence of some psychotropic drugs on the anti-immobility effects of serotonin reuptake inhibitors in the forced swimming test in mice
pp. 274-275(2)
Authors: Thieacute bot M.-H.; Da-Rocha M.A.; Puech A.J.

The additive effects of quinine on antidepressants in the forced swimming test in mice
pp. 275-275(1)
Authors: Guo W.Y.; Todd K.; Bourin M.

Measure of neuroreceptors and behaviour in a putative chronobiological model of affective disorders
pp. 275-275(1)
Authors: Schelstraete I.; Jeanjean A.P.; Weyers M.H.; Maloteaux J.M.

Effects of co-administration of anxiolytic-drugs on reversal by serotonin uptake inhibitors of deficit behavior in learned helplessness paradigm
pp. 275-276(2)
Authors: Martin P.; Lacroix P.; Billardon M.; Guillou N.; Puech A.

The antidepressant effects of 5-HT1A agonist buspirone in the learned-helplessness paradigm: a post-synaptic mediation
pp. 276-276(1)
Author: Martin P.

Antidepressant effects of milnacipran in the learned helplessness test in rats
pp. 276-276(1)
Authors: Lacroix P.; Rocher N.; Gandon J.M.; Panconi E.

Effect of sigma ligands on NMDA receptor function in the bulbectomy model of depression: a behavioural study in the rat
pp. 276-277(2)
Authors: Debonnel G.; Dryver E.; Lavoie N.

An investigation of the acute effects of sertraline in a rat social interaction test
pp. 277-277(1)
Authors: Lightowler S.; Kennett G.A.; Tulloch I.F.; Blackburn T.P.

A rapid antidepressant response may be induced by selectively activating postsynaptic serotonin_1a receptors
pp. 277-278(2)
Authors: Bergeron R.; de Montigny C.; Blier P.

Pindolol potentiates the effect of paroxetine on 5-HT efflux in the rat dorsal raphe nucleus
pp. 278-278(1)
Authors: Davidson C.; Stamford J.A.

Acute and chronic effects of imipramine on serotonergic function. Microdialysis studies in conscious rats
pp. 278-278(1)
Authors: Artigas F.; Bel N.

Effects of selective antidepressants on the sensitivity of the central alpha-2-adrenergic receptors
pp. 279-279(1)
Authors: Babinski T.; Totcacute S.; Marinkovicacute D.; Stanisavljevicacute D.; Paunovicacute V.R.

Protein kinase c activity and distribution in brain after chronic treatment with antidepressants
pp. 279-279(1)
Authors: Hrdina P.D.; Mann C.D.; Vu T.B.

Changes in the subcellular distribution of cAMP receptors after chronic treatment with fluvoxamine and paroxetine
pp. 279-280(2)
Authors: Mori S.; Caivano M.; Garbini S.; Dorigo A.; Zanardi R.; Perez J.; Racagni G.

Chronic antidepressant administration inhibits microtubule assembly in rat cerebral cortex
pp. 280-280(1)
Authors: Miyamoto S.; Asakura M.; Sasuga Y.; Imafuku J.; Gamo Y.; Osada K.

Effects of lithium on rat brain energy metabolism
pp. 280-280(1)
Authors: Imafuku J.; Pettegrew J.W.

Neuropeptides in central nervous system. Effects of lithium and electroconvulsive treatment
pp. 281-281(1)
Authors: Wahlund B.; Jimeneacute z P.; Haij K.; Danieli B.; Gruber S.; Matheacute A.A.; Stenfors C.; Theodorsson E.

Effect of lithium on inositol trisphophate formation in rat brain as determined by in vivo microdialysis
pp. 281-281(1)
Authors: Gur E.; Newman M.E.; Lerer B.

Pharmacological differences between selective serotonin reuptake inhibitors: interaction with 5-HT₂ and sigma binding sites in human brain in vitro
pp. 281-281(1)
Authors: Lowther S.; De Paermentier F.; Horton R.W.; Tulloch I.F.; Crompton M.R.

Motor effects of some selective serotonin reuptake inhibitors following direct injection into the red nucleus of the rat: evidence for involvement of sigma receptors
pp. 281-282(2)
Authors: Leonard B.E.; Faherty C.; Earley B.

The influence of different amitriptyline doses on its concentrations and pharmacokinetics
pp. 282-282(1)
Authors: Pokrajac M.; Miljkovicacute B.; Timotijevicacute I.

Contribution of lysosomal trapping to the tissue uptake of desipramine; its significance for pharmacokinetics and the pharmacokinetic interaction
pp. 282-283(2)
Authors: Daniel W.; Bickel M.H.; Honegger U.E.

Interactions between mianserin and opioid receptor subtype selectivity
pp. 283-283(1)
Authors: Pick C.G.; Backer M.M.; Schreiber S.

Involvement of serotoninergic system in the analgesic effect of tricyclic antidepressants
pp. 283-283(1)
Authors: Ghelardini C.; Galeotti N.; Bartolini A.

The Citalopram Challenge Test (CCT) as a probe for serotonergic function in depression
pp. 283-284(2)
Authors: Kapitany T.; Schindler S.D.; Barnas C.; Neumeister A.; Sieghart W.; Kasper S.

Effects of paroxetine and bupropion on event-related potentials and spectral frequency
pp. 284-284(1)
Authors: Camp-Bruno J.A.; Lifshitz K.; Lee K.; Linn G.S.; O'Keeffe R.T.

Fluoxetine, a selective 5-hydroxtryptamine uptake inhibitor, increases the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist
pp. 284-284(1)
Authors: Maj J.; Rogoacute z Z.; Skuza G.

An autoradiographic comparison of ³H-paroxetine and ³H-imipramine in human whole brain sections
pp. 284-285(2)
Authors: Miller J.; Bowery N.; Tulloch I.

Cerebral metabolic effects of fluvoxamine: an it in vivo [¹⁴C]2-deoxy-D-glucose study in rats
pp. 285-285(1)
Authors: Freo U.; Pizzolato G.; Merico A.; Ruggero S.; Dam M.; Battistin L.; Pietrini P.; Dani A.

Action of reboxetine on selective drug metabolizing enzymes in rat liver
pp. 285-285(1)
Authors: Fiorentini F.; Castelli M.G.; Dostert P.; Benedetti M.S.; Oesch F.; Arand M.

The dopamine system is involved in antidepressant sleep deprivation - a possible mechanismon of antidepressant action?
pp. 285-286(2)
Authors: Ebert D.; Albert R.; May A.; Kaschka W.P.; Barocka A.

Pharmacotherapy of depression in combination therapy with anxiolytics in non-comorbid depressive patients
pp. 286-286(1)
Author: Molnaacute r G.

Efficacy of fluoxetine in comparison to maprotiline and amitriptyline in major depression with anxious features
pp. 286-286(1)
Authors: Bugarski-Kirola D.; Totic S.; Damjanovic A.; Zivkovic D.

Tryptophan and Serotonin in Panic Disorder and Depression: Effect of Clomipramine Treatment
pp. 286-287(2)
Authors: Fekkes D.; Timmerman L.; Pepplinkhuizen L.

Double-blind comparison of three fixed doses of sertraline and placebo in patients with panic disorder
pp. 287-287(1)
Authors: DuBoff E.; England D.; Ferguson J.M.; Londborg P.D.; Rosenthal M.H.; Smith W.; Wiese C.; Wolkow R.M.

Psychopharmacological treatment of anorexia nervosa
pp. 287-287(1)
Authors: Cebollada A.; Chinchilla A.; Vega M.; Padiacute n J.J.; Montes J.M.; Guzmaacute n G.; Diacute az M.

Fluoxetine treatment of bulimia nervosa
pp. 287-288(2)
Authors: Vega M.; Chinchilla A.; Cebollada A.; Padiacute n J.J.; Guzmaacute n G.; Diacute az M.

The treatment of eating disorders with tianeptin
pp. 288-288(1)
Author: Atchkova M.

Fluvoxamine induced change of 5 HT receptor sensitivity in impulsive borderline personality disorder
pp. 288-288(1)
Authors: Rinne T.; Gans E.; Vernimmen R.; den Boer J.A.; Westenberg H.G.M.; van Tilburg W.

Practical aspects of long-term treatment
pp. 288-289(2)
Author: Malt U.F.

Stability as a factor of tricyclic antidepressants response in dysthymia
pp. 289-289(1)
Authors: Veltischev D.Y.; Gurevich J.M.; Seravina O.F.

The factor of antidepressant treatment response in dysthymia
pp. 289-289(1)
Authors: Veltischev D.Y.; Gurevich J.M.; Seravina O.F.

The treatment of dysthymia with sertraline: a double-blind placebo-controlled trial in dysthymic outpatients without major depression
pp. 289-290(2)
Authors: Guelfi J.D.; Wiseman R.L.

The treatment of dysthymic patients: fluvoxamine versus amitriptyline
pp. 290-290(1)
Authors: Amore M.; Ricci M.; Zazzeri N.

Therapeutical approach to dysthymia
pp. 290-290(1)
Authors: Fernaacute ndez G.; Ocio S.

Assessment of the evolution of anxiety during a treatment of major depressive disorders in ambulatory patients in general practice with fluoxetine (Prozac) 20 mg
pp. 290-291(2)
Authors: Mesters P.; Martens S.; Taymans J.

Onset of action of fluoxetine 20 mg (Prozac) among ambulatory patients suffering from depressive disorders
pp. 291-291(1)
Authors: Mesters P.; Sangeleer M.; Bussios G.; Bourgeois M.

Up-regulation of 5-HT_2C receptors by citalopram and fluoxetine in rat brain
pp. 291-291(1)
Authors: Syvauml lahti E.K.G.; Laakso A.; Pauml lvimauml ki E.-P.; Kuoppamauml ki M.; Hietala J.

The effects of fluoxetine in patients receiving nutritional counselling for bulimia nervosa
pp. 291-292(2)
Authors: Russell J.; Beumont P.; Touyz S.; Buckley C.; Lowinger K.; Talbot P.; Dowton L.; Hasky R.; Allars H.; Johnson G.

Clinical differences in response to mianserin and fluoxetine in depressive patients
pp. 292-292(1)
Authors: Lavergne F.; Berlin I.; Payan C.; Besanccedil on G.

Combined treatment with serotonin reuptake selective inhibitors in depression (I). Evaluation of therapeutic efficacy
pp. 292-292(1)
Authors: Valverde J.I.F.; Loza A.A.S.; Montes M.J.R..; Martiacute nez M.L.D.; Caballero J.L.V..

Combined treatment with serotonin reuptake selective inhibitors in depression (II). Aspects concerning tolerance and toxicity in clinical practice
pp. 292-293(2)
Authors: Loza A.A.S.; Valverde J.I.F.; Montes M.J.R..; Martiacute nez M.L.D.; Caballero J.L.V..; Docio E.Q.

Antidepressants and neuroleptic malignant syndrome
pp. 293-293(1)
Authors: Assion H.J.; Heinemann F.; Laux G.

Dosulepine -- an adiuvant treatment of oncological pain
pp. 293-293(1)
Authors: Tondlavaacute H.; Jakoubkovaacute J.; Bascaron tecky J.

Idiopathic blepharospasm treated successfully with fluoxetine: do SSRI's have some dopaminergic effect?
pp. 293-294(2)
Authors: Schreiber S.; Pick C.G.

Sleep quality and day-time alertness in responders and non-responders to fluoxetine
pp. 294-294(1)
Authors: Dossenbach M.; Meszaros K.; Meyer J.W.

Possible association of suicidal behavior with selective serotonin reuptake inhibitors. The effect of citalopram on five depressed patients
pp. 294-294(1)
Authors: Trikkas G.; Markianos M.; Trikka D.

Acute and subchronic effects of mirtazapine (1530 mg nocte) and mianserin (3060 mg nocte) on psychomotor and actual driving performance and sleep in healthy, young volunteers
pp. 294-295(2)
Authors: Ramaekers J.G.; Muntjewerff N.D.; O'Hanlon J.F.

Compliance with different classes of antidepressant drugs
pp. 295-295(1)
Authors: Koutouvidis N.; Zacharakis C.

Efficacy of antidepressant medications for treatment of mild and moderate depression
pp. 295-295(1)
Authors: Fonzo V.; Scotta M.; Rocca P.; Zanalda E.; Ravizza L.

Changes in acute phase proteins in depressed patients, during treatment with fluoxetine and venlafaxine
pp. 295-296(2)
Authors: Sluzewska A.; Houml rning-Rohan M.; Sobieska M.; Rybakowski J.K.; Amsterdam J.D.

Serotonin-related symptoms and adrenergic status in depressed patients treated with clomipramine
pp. 296-296(1)
Authors: Lejoyeux M.; Rouillon F.; Adeacute s J.

Pharmacotherapy in depression during switch from depression to mania in patients with bipolar affective disorder (BD)
pp. 296-296(1)
Author: Koszewska I.

Multiple and single dose pharmacokinetics of milnacipran in major depressive patients
pp. 296-297(2)
Authors: Retz W.; Becker T.; Schmidtke A.; Riederer P.; Beckmann H.

Moclobemide in the treatment of depressive syndrome in schizophrenia
pp. 297-297(1)
Authors: Jasovic-Gasic M.; Nikolic-Balkoski G.; Totic S.; Acimovic B.; Kuzmanovic V.

The possibilities of automid (moclobemide) administration in the treatment of affective disorders
pp. 297-297(1)
Authors: Timotijevicacute I.; Kovaccaron evicacute S.; Tomovicacute A.; Kosticacute D.

Treatment of severe recurrent major depression: comparative efficacy and tolerability of moclobemide and impiramine
pp. 298-298(1)
Authors: Hochstrasser B.; Ferrero F.; Gachoud J.-P.; Gasser U.E.; Mascetti R.; Meyer J.W.; Wacker H.R.

Efficacy of moclobemide-therapy in depressed patients -- above 65 years old
pp. 298-298(1)
Author: Radics J.

Dimensional assessment of onset of action of antidepressants -- a comparative study of moclobemide versus clomipramine in depressed patients with blunted affect and psychomotor retardation
pp. 298-299(2)
Authors: Jouvent R.; Payan C.; Mikkelsen H.; Fermanian J.; Millet V.; Dufour H.

Comparison of the effects of nefazodone and fluoxetine on sleep architecture and sleep efficiency in depressed patients
pp. 299-299(1)
Authors: Armitage R.; Yonkers K.; Rush A.J.; Cole D.; Novak K.

Delusional depression: SSRIs vs tricyclics responsiveness
pp. 299-299(1)
Authors: Conte G.; Calzeroni A.; Ferrari R.; Guarneri L.; Sacchetti E.

SSRIs: a homogeneous class of antidepressants with non homogeneous responsiveness in major depression
pp. 299-300(2)
Authors: Conte G.; Calzeroni A.; Guarneri L.; Pergami A.; Sacchetti E.

Dopamine receptor binding in major depression: changes before and after treatment with selective serotonin reuptake inhibitors
pp. 300-300(1)
Authors: Klimke A.; Larisch R.; Janz A.; Vosberg H.; Muuml ller-Gauml rtner H.W.; Gaebel W.

Effect of lorazepam on the pharmacokinetics of reboxetine in healthy volunteers
pp. 300-300(1)
Authors: Fiorentini F.; Poggesi I.; Jannuzzo M.G.; Dostert P.; Strolin Benedetti M.; Seiberling M.

Pharmacokinetics of reboxetine in healthy volunteers of different ages
pp. 300-300(1)
Authors: Jannuzzo M.G.; Pellizzoni C.; Poggesi I.; Rocchetti M.; Frigerio E.; Dostert P.; Ryde M.; Karlmark B.; Rouml nn O.; Strolin Benedetti M.

Effect of reboxetine on the pharmacokinetics of lorazepam in healthy volunteers
pp. 300-301(2)
Authors: Jannuzzo M.G.; Dostert P.; Strolin Benedetti M.; Bosc M.; Renoux A.

Endocrine response to lithium challenge in unmedicated rapid-cycling patients
pp. 301-301(1)
Authors: Whybrow P.; Redei E.; Gyulai L.

Lithium treatment and suicide prevention in affective disorders
pp. 301-301(1)
Author: Ahrens B.

Open comparative study of lithium carbonate, carbamazepine and sodium valproate prophylactic use in affective and schizoaffective disorders
pp. 301-302(2)
Authors: Mosolov S.N.; Kostukova E.G.; Kouzavkova M.V.

Comparison of carbamazepine and beta-endorphin levels in manic states treatment
pp. 302-302(1)
Author: Procic V.A.

Experience with lithium/fluvoxamine combination: 36 cases
pp. 302-302(1)
Authors: Hopwood S.E.; Ashford J.J.; Prescott P.

A pilot study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia
pp. 302-303(2)
Authors: Fava M.; Nierenberg A.A.; Quitkin F.M.; Zisook S.; Rosenbaum J.F.

Sleep in depressed outpatients during treatment with fluvoxamine -- a home-based study
pp. 303-303(1)
Authors: Wilson S.J.; Bell C.; Coupland N.J.; Nutt D.J.

Fluvoxamine reduces somatic symptoms and is well tolerated in elderly depressed patients: results from the oldest reported population treated with a selective serotonin reuptake inhibitor
pp. 303-304(2)
Authors: Jaquenoud E.; Hochstrasser B.; Kat M.

Comparison of the safety and tolerance of fluvoxamine and sertraline in depressed outpatients
pp. 304-304(1)
Authors: Nemeroff C.B.; Ninan P.T.; Ballenger J.C.; Feighner J.; Greist J.H.; Patterson W.M.

Comparison of fluvoxamine and fluoxetine in major depression
pp. 304-304(1)
Authors: Rapaport M.; Coccaro E.; Sheline Y.; Holland P.; Perse T.; Fabre L.

Safety and tolerability of fluvoxamine in adolescent depression
pp. 304-305(2)
Authors: Alfonso M.; Ferrer R.; Such P.

Antidepressant actions on peripheral visual detection mechanisms in humans
pp. 305-305(1)
Authors: Weinstein A.; Wilson S.; Bailey J.; Nutt D.

A multicentre study of nefazodone and sertraline in depressed outpatients
pp. 305-306(2)
Authors: Burns T.; Kosky N.; Balasubramaniam K.; D'Souza J.; Andrews G.; Freeman C.; Buckingham S.; Hawkings E.; Mellors K.; Ascher A.

A multicentre comparison of nefazodone and paroxetine in depressed outpatients
pp. 306-306(1)
Authors: Baldwin D.; Hawley C.; Abed R.; Maragakis B.; White A.; Cox J.; Pover G.; Von Frenkell R.

Down regulation of 5-HT_2A receptors after chronic treatment with remeron
pp. 306-306(1)
Authors: Berendsen H.H.G.; Broekkamp C.L.E.; van Delft A.M.L.

Perspectives of use of calcium channels blockers for treatment of affective disorders (experimental data)
pp. 306-307(2)
Author: Kozlovsky V.L.

Effect of venlafaxine on rate and extent of improvement of depressive symptoms
pp. 307-307(1)
Authors: Hackett D.; Haudiquet V.; Danjou P.

An overview of the dose-response efficacy of venlafaxine with respect to treatment in different subclassifications of depressive illness
pp. 307-307(1)
Authors: Guichoux J.Y.; Hackett D.

Cardiac safety of venlafaxine
pp. 307-308(2)
Author: Danjou P.

A randomised, double-blind, comparison of the efficacy and safety of venlafaxine (75 to 150 mg/day) versus fluoxetine (20 mg/day) in depressed outpatients
pp. 308-308(1)
Authors: Salinas E.; Nicholas T.; Hackett D.

A randomized double-blind comparison of venlafaxine, imipramine and placebo in general practice patients with mild moderate depression
pp. 308-308(1)
Authors: Blanchard C.; Hackett D.; Danjou P.; Nicholas T.

Acute and continuation therapy with sertraline in major depression: a large-scale multicenter study
pp. 308-309(2)
Authors: Floris M.; De Nayer A.R.; Janssen F.; Van Houdenhove B.; Iancu H.; Boxus A.

A double-blind, multicentre study in primary care comparing paroxetine and clomipramine in patients with depression with associated anxiety
pp. 309-309(1)
Author: Hunter B.

A naturalistic prospective study of the efficacy and tolerability of fluoxetine in 244 unselected psychiatric outpatients. The importance of co-morbidity as a predictor of response
pp. 309-309(1)
Author: Blacker C.V.R.

The effects of trazodone on sleep: a clinical and EEG study in patients with major depression
pp. 309-310(2)
Authors: Arriaga F.; Paiva T.; Cavaglia F.; Pinheira G.

Trazodone and sleep disturbances induced by brofaromine
pp. 310-310(1)
Authors: Haffmans P.M.J.; Vos M.S.

Efficacy and safety of mirtazapine vs trazodone in hospitalised depressed patients
pp. 310-310(1)
Author: Van Moffaert M.

Evaluation of the potential pharmacokinetic interaction of venlafaxine and carbamazepine
pp. 310-311(2)
Authors: Wiklander B.; Danjou P.; Rolan P.; Tamin S.K.; Toon S.

The efficacy of tianeptine: an Indian study of one hundred and sixteen non-psychotic depressed patients
pp. 311-311(1)
Authors: Parikh R.M.; Sonwalla S.B.; Shah L.P.; Doshi B.S.

Paroxetine for treating depression in adolescents
pp. 311-311(1)
Authors: Rodriguez Ramos P.; Mardomingo Sans M.J.; San Sebastian Cabases J.; de Dios Vega J.L.; Sordo Sordo L.

Effect of clomipramine versus placebo on social adjustment in residual depression
pp. 311-312(2)
Authors: Rouillon F.; Waintraub L.; Markabi S.; Lancrenon S.

Fluoxetine in therapy of persons with PTSD
pp. 312-312(1)
Authors: Folnegovicacute Scaron malc V.; Folnegovicacute Z.; Kocijan D.; Kozaricacute D.; Makaricacute G.; Mimica N.

Neuroleptics in the therapy of delusional depression
pp. 312-312(1)
Authors: Cvjetkovicacute M.; Knezcaron evicacute A.; Nedicacute A.

The influence of doxepine treatment upon the changes of triglycerides and cholesterol level in anorexic patients
pp. 312-313(2)
Authors: Rajewski A.; Rajewska J.; Chlebowski T.

Fluvoxamin (Avoxin-KRKA) in the pharmacotherapy of mood disorders in elderly
pp. 313-313(1)
Authors: Mahnik M.; Hotujac L.; Vukelja D.; Mandicacute K.

Treatment of depressions in elderly GP-patients
pp. 313-313(1)
Author: Mikhailova N.M.

Clinical efficacy of paroxetine in elderly outpatients
pp. 313-314(2)
Authors: Zarattini F.; Testa L.

SSRIs in the treatment of depressed out patients aged 70 years and older
pp. 314-314(1)
Authors: Newhouse P.A.; Finkel S.I.; Richter E.M.

Double-blind comparison of sertraline and nortriptyline in late-life depression
pp. 314-314(1)
Authors: Finkel S.I.; Richter E.M.

Sertraline: an assessment of clinical benefit and cost in the UK
pp. 314-315(2)
Authors: Johnson N.J.; Lane R.

An open study of sertraline in fibromyalgia syndrome
pp. 315-315(1)
Authors: Syuertsen J.O.; Smedsrud T.; Lane R.M.

Combined therapy in treating poststroke depression
pp. 315-315(1)
Author: Marko M.

The non-responding major depressive patient -- the treatment-refractory major depressive patient
pp. 315-315(1)
Author: Drolsum B.A.

Analysis of the Hamilton depression rating scale factors -- fluoxetine vs. maprotiline
pp. 315-316(2)
Authors: Stankovicacute Z..; Zcaron ivkovicacute -Milovanovicacute D.; Bugarski-Kirola D.; Damjanovicacute A.

Effects of befloxatone on psychomotor performance and cognitive functions in elderly subjects
pp. 316-316(1)
Authors: Patat A.; Gandon J.M.; Le Coz F.; Durrieu G.; Cimarosti I.; Allain H.; Rosenzweig P.

Plasma concentration of MCPP after single oral dose administration of trazodone and MCPP in humans
pp. 316-316(1)
Authors: Lawlor B.A.; Radcliffe J.; Sunderland T.; Murphy D.L.

The neurochemical and behavioural effects of the isomers of mirtazapine in normal rats
pp. 316-317(2)
Authors: Norman T.R.; McGrath C.J.; Burrow G.D.

Effect D.N.Uznadze in paranoid schizophrenics: clinical and treatment perspectives
pp. 317-317(1)
Author: Pkhidenko S.V.

Soluble interleukin-6 receptors in schizophrenia: preliminary results
pp. 317-317(1)
Authors: Muuml ller N.; Empl M.; Putz A.; Schwarz M.; Ackenheil M.

Outcome predictors in first episode schizophrenia
pp. 317-318(2)
Authors: Amore M.; Magnani K.; D'Ambrosio S.; Mesa J..M.

Predictors of treatment compliance in long-term mentally ill
pp. 318-318(1)
Author: Middelboe T.

Are regional cerebral blood flow studies using single photon emission computed tomography (SPECT) reproducible in schizophrenia? Presentation of the protocol
pp. 318-318(1)
Authors: Walter M.; Leboul D.

Investigating dopamine receptor binding with PET and SPECT ligands in schizophrenia: clinical and methodological considerations
pp. 318-319(2)
Authors: Klimke A.; Boy C.; Muuml ller-Gauml rtner H.W.; Gaebel W.

Differential effects of S-ketamine and R-ketamine on psychopathology and brain energy metabolism measured by FDG-PET in humans
pp. 319-319(1)
Authors: Vollenweider F.X.; Leenders K.L.; Oslashye I.; Scharfetter C.; Angst J.

Eye fixations and recognition memory in schizophrenia
pp. 319-320(2)
Authors: Fleury E.; Buquet C.; Thomas P.; Goudemand M.; Hache J.C.; Charlier J.R.

Cerebral ventricles in chronic schizophrenia and ageing
pp. 320-320(1)
Authors: Medvedev A.V.; Valova O.A.; Savvateeva N.J.U.; Zharkova N.B.

Impaired performance on tests sensitive to fronto-subcortical dysfunction is related to both the positive and the negative dimensions of schizophrenia
pp. 320-320(1)
Authors: Mignone M.L.; D'Amato A.C.; Saviano P.; Mucci A.; Galderisi S.; Maj M.

Increased allergic reactivity of atopic type in major psychoses
pp. 320-321(2)
Authors: Dacedil bkowska M.; Rybakowski J.K.

Leucocyte arylsulphatase A activity in schizophrenia and depression
pp. 321-321(1)
Authors: Pelescaron A.M.; Jakovljevicacute M.; Kraccaron un I.; Ccaron accaron icacute A.; Miliccaron evicacute Z..

Clinical dimensions and neuroleptic dosage in newly admitted schizophrenic patients
pp. 321-321(1)
Authors: Troisi A.; Spalletta G.; De Angelis F.; Inzerilli G.; Ciani N.; Pasini A.

Functional etiology of schizophrenia as a new approach for specific treatment
pp. 321-321(1)
Authors: Trimarchi M.; Papeschi L.L.; Russo P.; Trimarchi C.P.; Guasco P.; Lugaresi E.; Nicolini M.

Fenfluramine challenge test in schizophrenia
pp. 322-322(1)
Authors: Mohr P.; Scaron raacute movaacute L.; Libiger J.